Senses Disorder TRIZ Cases

Topical Ranpirnase enzymatically degrades viral RNA to suppress replication, preventing cornea scarring from adenovirus infection.

Sialic-acid decorated nanoparticles agonize Siglec receptors to inhibit complement activation and block viral entry into host cells.

Isothiazole derivatives inhibit tubulin polymerization and disrupt neovasculature blood flow to treat multi-drug resistant proliferative disorders.

Phenylephrine hydrochloride and atropine sulphate achieve synergistic mydriasis while minimizing side effects.

Carboxyl-containing polymer suspension delivers dexamethasone to treat blepharitis while minimizing antibiotic resistance risks.

Chelating agents bind metal ions to prevent suspending agent deactivation, ensuring physical stability for intraocular administration.

ABCF1 inhibitors down-regulate aberrant DNA sensing pathways, preventing autoimmune diseases caused by cytosolic DNA accumulation.

C74 targets Pfn1:actin interaction to overcome VEGF resistance in renal cell carcinoma and ocular diseases.

Fluorine substitution at C-7 and a tetrazole group at C-1 enhance metabolic stability while reducing IP agonist activity.

TGF-beta antagonists reduce pathological signaling to manage aortic root growth and skeletal issues in Marfan syndrome.

A Wharton's jelly hydrogel scaffold mimics the extracellular matrix to support cell proliferation.

Compounds activate eIF2B to balance stress signaling with protein synthesis initiation.

Whey protein isolate microencapsulates lutein to resolve poor solubility, delivering antioxidant protection against retinal blue light damage.

Alkyl carbamate derivatives inhibit FAAH enzyme activity, resolving limited therapeutic efficacy for pain and neurological conditions.

A contact lens incorporates a sacrificial PRG4 mechanism to reversibly bind lubricating agents and reduce ocular surface friction.

A tear glucose-responsive hydrogel releases reactive oxygen species under near-infrared irradiation to target pathogens in the eye.

Small molecule fused imidazole and pyrazole derivatives overcome structural diversity limits of macromolecular inhibitors while maintaining potent TNFα binding.

Segmented AT1R biased agonists resolve the reliability-versatility trade-off in GPCR drug design by enabling precise pathway control.

Rho-kinase inhibitors reverse cellular senescence and improve mitochondrial function to treat Hutchinson-Gilford progeria syndrome.

Black tea flavanoids stimulate bifidobacteria growth, avoiding refrigeration needs and formulation issues.

Cyclodextrin inclusion complexes resolve low aqueous solubility and chemical instability of HDAC inhibitors, enabling stable intravenous formulations.

Apaf-1 inhibitor compounds block apoptosome formation to preserve organ viability during storage and transplantation.

Reduced folate forms cross the blood-retina barrier to enhance retinal blood flow, addressing limitations of inactive folic acid supplements.

Thioether crosslinking prevents burst effects, ensuring sustained drug delivery over months.

CP-25 modifies paeoniflorin structure to boost saliva flow while suppressing immune response, addressing side effects of conventional immunosuppressive agents.

Modulator compounds address defective protein trafficking by enhancing ion transport efficiency in cystic fibrosis treatment.

Cyclic olefin resin containers suppress wetting of ophthalmic compositions, eliminating liquid residues and preserving aromaticity.

Segmented alcohol extraction isolates an ethyl acetate fraction that reduces adipose tissue volume by blocking new blood vessel formation.

Formula I oxindole compounds protect mitochondrial functions against oxidative stress, addressing safety and efficacy issues in degenerative disease treatments.

Mechanical vibration improves reagent distribution and cell lysis, reducing processing time while preserving extracellular matrix integrity.

Antibodies bind specific activation sites on the sodium potassium ATPase alpha subunit to increase enzymatic activity.

A chimeric rhodopsin protein fuses a Chlamydomonas N-terminal region with Volvox channel rhodopsin to boost cell membrane expression efficiency.

Heterocyclic modifications reduce immunosuppressive side effects while maintaining cyclophilin A inhibition for dry eye therapy.

Dual siRNA oligonucleotides target TSC1 and TSC2 genes, addressing genetic diversity in retinal dystrophies while maintaining therapeutic specificity.

Topical roflumilast migrates laterally through ocular surface tissues to elevate drug concentration in anterior segments.

PLGA nanoparticles solubilize hydrophobic photosensitizers via the EPR effect, preventing thromboembolic risks from poor aqueous solubility.

mTORC1 inhibitors reduce drusen formation and prevent geographic atrophy progression in age-related macular degeneration.

Aniline-substituted diarylureas achieve selective p38 MAP kinase inhibition to reduce toxicity associated with non-selective inflammatory disease treatments.

Combining BI-1356 with metformin improves glycemic control through dual mechanism action.

Selective heterocyclic inhibitor targets TYK2 JH2 domain, reducing anemia and liver damage risks from non-selective JAK blockade.

Targeted N-terminal and C-terminal modifications boost inhibitory strength on tumor cells, resolving limited specificity in existing GH-RH antagonists.

Human monoclonal antibodies bind nerve growth factor to neutralize biological activity, addressing chronic pain side effects from conventional treatments.

Mutated bispecific antibodies reduce systemic toxicity while extending intravitreal half-life.

Antibodies neutralize hemopexin to restore blood-retinal barrier integrity, addressing late-stage treatment limitations.

Monohydroxyphenyl radicals enable passive diffusion of active ingredients across cell membranes, eliminating complex delivery vehicles.

Substituted oxopyridine derivatives inhibit factor XIa and plasma kallikrein to reduce thrombin production.